Prognostic Benefit of >/=6 Cycles of Neoadjuvant Chemotherapy for Advanced Ovarian, Tubal, and Peritoneal Cancers. Kondo E, Nimura R, Maki S, Kaneda M, et al. Anticancer Res 2021;41:4157-4161.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kondo E, Nimura R, Maki S, Kaneda M, et al. Prognostic Benefit of >/=6 Cycles of Neoadjuvant Chemotherapy for Advanced Ovarian, Tubal, and Peritoneal Cancers. Anticancer Res 2021;41:4157-4161.
PMID: 34281887